These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9536273)

  • 1. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
    Andreansky S; He B; van Cott J; McGhee J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Gene Ther; 1998 Jan; 5(1):121-30. PubMed ID: 9536273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
    Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
    Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
    Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
    J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene.
    Benedetti S; Dimeco F; Pollo B; Cirenei N; Colombo BM; Bruzzone MG; Cattaneo E; Vescovi A; Didonato S; Colombo MP; Finocchiaro G
    Hum Gene Ther; 1997 Jul; 8(11):1345-53. PubMed ID: 9295129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
    Toda M; Martuza RL; Kojima H; Rabkin SD
    J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
    Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
    Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
    Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
    Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.
    Ram Z; Walbridge S; Heiss JD; Culver KW; Blaese RM; Oldfield EH
    J Neurosurg; 1994 Mar; 80(3):535-40. PubMed ID: 8113867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma.
    Kanno H; Hattori S; Sato H; Murata H; Huang FH; Hayashi A; Suzuki N; Yamamoto I; Kawamoto S; Minami M; Miyatake S; Shuin T; Kaplitt MG
    Cancer Gene Ther; 1999; 6(2):147-54. PubMed ID: 10195881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.
    Markert JM; Cody JJ; Parker JN; Coleman JM; Price KH; Kern ER; Quenelle DC; Lakeman AD; Schoeb TR; Palmer CA; Cartner SC; Gillespie GY; Whitley RJ
    J Virol; 2012 May; 86(9):5304-13. PubMed ID: 22379082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
    Miyatake S; Martuza RL; Rabkin SD
    Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
    Chambers R; Gillespie GY; Soroceanu L; Andreansky S; Chatterjee S; Chou J; Roizman B; Whitley RJ
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1411-5. PubMed ID: 7877992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.
    Andreansky SS; He B; Gillespie GY; Soroceanu L; Markert J; Chou J; Roizman B; Whitley RJ
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11313-8. PubMed ID: 8876132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
    Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
    Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer.
    Wei MX; Tamiya T; Hurford RK; Boviatsis EJ; Tepper RI; Chiocca EA
    Hum Gene Ther; 1995 Apr; 6(4):437-43. PubMed ID: 7612701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector.
    Herrlinger U; Kramm CM; Aboody-Guterman KS; Silver JS; Ikeda K; Johnston KM; Pechan PA; Barth RF; Finkelstein D; Chiocca EA; Louis DN; Breakefield XO
    Gene Ther; 1998 Jun; 5(6):809-19. PubMed ID: 9747461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
    Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
    Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.